$71.03
+0.42 (+0.59%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TARS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
12 interventional · 3 with posted results
Held by 13 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, D. E. Shaw & Co., Inc., Squarepoint Ops LLC, Artisan Partners Limited Partnership, CITADEL ADVISORS LLC, +8 more) · FINRA short interest 6.6 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 6 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick ExposureNCT07562087The Incidence of Treatment Emergent Adverse Events From BaselineRandomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Drug: TP-05 (lotilaner) Low Dose, TP-05 (lotilaner) High Dose, Placebo | Lyme Disease | 722 | Oct 2027 | ≤ 438 d | 2026-07-09 |
| Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)NCT07443202Incidence of Treatment Emergent Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 2 | Enrolling by invitation | Drug: lotilaner, Vehicle | Ocular Rosacea | 155 | 2026-12-31 | in 134 d | 2026-03-02 |
| Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens WearersNCT06182358Reduction of collarettes at Day 43Randomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: Lotilaner ophthalmic solution, 0.25%, Vehicle control | Demodex Blepharitis | 145 | 2025-01-27actual | — | 2025-07-02 |
| A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05NCT05387083The Incidence of treatment emergent adverse events from baselineRandomized · Quadruple-masked · Other | Phase 2 | Completed | Drug: Low Dose TP-05, High Dose TP-05, Placebo Comparator | Healthy Volunteer | 30 | 2024-06-26actual | — | 2024-09-19 |
| Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With DemodexNCT06054217Treatment Emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 2 | Unknown status | Drug: Vehicle of TP-03 | Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis, Demodectic Blepharitis | 36 | 2024-06-15 | — | 2024-04-09 |
| Study of TP-04 in Participants With Papulopustular RosaceaNCT05838170The incidence of treatment emergent adverse events from baselineRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Lotilaner Gel, 2.0% · Other: Vehicle control gel | Papulopustular Rosacea | 37 | 2023-11-13actual | — | 2023-11-24 |
| Study to Evaluate the Food Effect of TP-05 in Healthy ParticipantsNCT05720364Concentration of TP-05 in whole bloodRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: TP-05 (lotilaner oral), fasted group, TP-05 (lotilaner oral), high-fat group, TP-05 (lotilaner oral), low-fat group | Healthy | 42 | 2023-05-30actual | — | 2023-06-28 |
| Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGDNCT05454956results2025-10-01Number of Participants With Treatment Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: TP-03, TP-03 Vehicle | Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation | 39 | 2023-05-18actual | — | 2025-10-01 |
| Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex BlepharitisNCT04784091results2023-12-21The Proportion of Participants Cured Based on Their Collarette Score of 0 for the Upper Eyelid.Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: TP-03, TP-03 Vehicle | Blepharitis | 412 | 2022-05-09actual | — | 2023-12-21 |
| A Pharmacokinetic Study of TP-05 in Healthy SubjectsNCT05138796Incidence of treatment emergent adverse events (TEAEs)Randomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: TP-05 (lotilaner oral capsules), Placebo | Healthy | 67 | 2022-03-25actual | — | 2022-08-03 |
| A Six Week Pharmacokinetic Study of TP-03 in Healthy SubjectsNCT05138861To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.Open-label · Basic science | Phase 1 | Completed | Drug: TP-03 (Lotilaner Ophthalmic Solution), 0.25% | Healthy | 24 | 2021-09-03actual | — | 2024-04-12 |
| Safety and Efficacy of TP-03 for the Treatment of Demodex BlepharitisNCT04475432results2023-12-21Proportion of Participants Cured Based on a Collarette Score at Day 43.Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: TP-03, 0.25%, TP-03 Vehicle | Blepharitis | 421 | 2021-05-04actual | — | 2023-12-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19